^
Association details:
| Biomarker: | KIF5B-MET fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma
Excerpt:
Because we identified the KIF5B-MET fusion gene, the patient was treated in June 2016with crizotinib, which was originally developed as a c-MET inhibitor after various salvage therapies. The patient exhibited a dramatic response with a long duration (10 months) (Fig. 2)...
DOI:
10.1016/j.jtho.2017.10.014
Source:
Title:
Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients
Excerpt:
The first patient, identified with the KIF5B-MET gene fusion, was a 33-year-old female with stage IV LADC...Two weeks after off-label treatment with crizotinib...A subsequent PET/CT showed a response with a decrease in tumor size and FDG uptake....Crizotinib leads to a clinical response in patients with MET rearrangements.
DOI:
10.1158/1078-0432.CCR-17-3001
